YD Bio Limited (NASDAQ: YDES) is a biotechnology company that regularly issues news on DNA methylation‑based cancer detection, precision diagnostics, ophthalmologic innovations, and stem cell and exosome therapies. Its press releases describe progress across oncology diagnostics, limbal stem cell–derived exosome platforms, and clinical‑trial supply operations, giving investors and observers insight into how the company is advancing its programs.
News updates for YD Bio often cover developments in its collaboration with EG BioMed, including expansion of the OkaiDx™ cfDNA‑methylation blood‑based testing platform for cancers such as pancreatic, colorectal, and breast cancer. Announcements have detailed CLIA and CAP accreditation for EG BioMed’s U.S. laboratory, expanded state‑by‑state access to laboratory‑developed tests, and clinical research data for early pancreatic cancer detection assays that remain under validation and are not yet FDA‑cleared or approved.
Another recurring theme in YD Bio’s news is ophthalmology. Releases describe milestones in limbal stem cell and exosome‑based platforms, FDA 510(k) clearance for Exovisse contact lenses, over‑the‑counter monograph compliance for Exovisse artificial tears, and planned clinical programs for eye conditions. The company also reports on regulatory filings such as Drug Master Files for limbal stem cells and exosomes, as well as planned clinical studies in Taiwan and regulatory strategies in the United States.
Corporate and capital markets developments appear in YD Bio’s news flow as well, including the closing of its business combination with Breeze Holdings Acquisition Corp., listing on the Nasdaq Global Market, and a non‑binding Memorandum of Understanding to merge with EG BioMed. Readers following YDES news can expect coverage of scientific presentations, intellectual property updates, facility plans such as a proposed California operations center, and governance or auditor changes disclosed through SEC reports and press releases.
YD Bio (Nasdaq: YDES) announced a collaboration with affiliate EG BioMed and digital health provider JoiiUp to integrate cancer-risk assessment into JoiiSports.
The jointly developed AI Cancer Risk Assessment uses self-reported health information to generate risk reports and lifestyle recommendations. It was developed with three Taipei Medical University-affiliated hospitals and validated using over 1,200 clinical records. Initial deployment is expected to focus on JoiiUp’s existing corporate partner network. The companies plan to expand to healthcare institutions following successful corporate implementation.
The assessment is a risk-stratification and health guidance tool, not a diagnostic or screening test. Its output does not represent the probability of developing cancer, and it cannot replace professional medical evaluation or recommended cancer screening.
YD Bio (Nasdaq: YDES) and EG BioMed launched an online AI cancer risk assessment covering ten cancer types at US$10 promotional pricing. Available in English and Chinese, it uses a 52-question survey of self-reported health information to generate personalized risk-factor reports. The regular price is US$50.
The assessment sits upstream of the companies' laboratory and clinical services. Reports may reference related blood tests for discussion with a physician, who decides whether testing is appropriate. The output does not represent the probability of developing cancer and is not intended for diagnosis, screening, early detection or treatment decisions.
YD Bio entered a memorandum of understanding to merge with EG BioMed in January 2026. The company anticipates closing in 2026, subject to regulatory approvals and finalizing definitive agreements.
YD Bio (Nasdaq: YDES) reported unaudited results for the six months ended June 30, 2026, with net revenue rising 315% to $0.85 million and gross profit up to $0.27 million. Revenue growth was driven mainly by higher sales of drugs and medical products, including a single Fetroja order of $327,060 that represented 39% of net revenue. Operating expenses increased 73% to $3.5 million, widening the operating loss to $3.23 million.
A $9.85 million non‑cash gain from the change in fair value of warrant liabilities turned prior‑year net loss into net income of $6.7 million. Cash fell to $2.66 million, while warrant liabilities dropped to $4.52 million and shareholders’ equity moved from a deficit to $4.47 million. The company also advanced exosome and diagnostics platforms, expanded telehealth and lab coverage, and signed strategic agreements including a planned acquisition of SSMC and a U.S. agency role for YC Biotech.
YD Bio (Nasdaq: YDES) announced that a peer-reviewed review article titled “Beyond Bone Health: Exploring the ‘Heart–Brain–Bone’ Axis Modulated by Lipid-Soluble Nutrients (Omega-3, Vitamin D3, and Vitamin K2)” has been published open access in Nutrients, an MDPI journal. The paper, accepted on August 18, 2026 and published August 19, 2026, was co-authored by YD Bio’s scientific team and physicians from the Taiwan Chronic Disease Healthcare Association, the Future Health Institute, and Taipei Medical University Hospital. The article synthesizes evidence on how omega-3 fatty acids, vitamin D3 and vitamin K2 may influence shared pathways across cardiovascular, central nervous and skeletal systems, and it formalizes a research component within YD Bio’s recently announced physician-partnership and nutraceutical initiative in Taiwan.
YD Bio (Nasdaq: YDES) launched two physician co-developed chrono-nutrition products in Taiwan as its initial step toward a broader physician-partnership ecosystem and consumer health commercialization strategy. The offerings comprise a daytime lipid-soluble “Golden Triangle” formulation and a nighttime zinc-plus-calcium formulation, created with the Taiwan Chronic Disease Healthcare Association (CDHA) and the Future Health Institute (FHI), a physician-led health education platform.
This model places practicing clinicians at the center of defining formulation needs based on their patient populations, while YD Bio provides product development, sourcing, quality oversight and commercialization. Each product carries the CDHA certification mark and an FHI recommendation. According to the company, the model is intended to be capital-light, support recurring consumer revenue, and build relationships with health-conscious consumers that may later connect to YD Bio’s regulated diagnostics, clinical services and life science offerings. The daytime formula aligns with an internal research interest on omega-3, vitamin D3 and vitamin K2, supported by a review manuscript currently under journal peer review.
YD Bio (Nasdaq: YDES) highlighted a peer‑reviewed open‑access publication in Bioengineering (2026, Vol. 13, Article 853), co-authored with Taipei Medical University and Taipei Medical University Hospital. The study presents a fully reproducible, data-driven framework using public gene and protein databases to investigate keratoconus.
Researchers created a Cargo Prioritization Score (CPS) to rank candidate molecules for potential stem-cell-derived exosome–based regenerative therapies, identifying proteins including COL1A1, FN1, COL4A1, COL3A1, COL5A1, and MMP1. According to YD Bio, the work is an early computational step to guide future laboratory validation and does not assess therapeutic safety or efficacy.
YD Bio (Nasdaq: YDES) launched a six-month pilot collaboration with Numia Health, YD Bio US, and EG BioMed US to test a cross-border clinical workflow for physician-ordered, blood-based OkaiDx cancer tests for eligible patients in British Columbia, Canada.
The Pilot, capped at up to 50 patient episodes in the Lower Mainland, will route samples via Numia Health’s physician and mobile phlebotomy network to EG BioMed US’s CLIA-certified, CAP-accredited lab in Bothell, Washington. The program targets breast, colorectal, pancreatic, liver, and gastrointestinal cancers and is intended to assess scalability and patient experience ahead of any broader, non-exclusive commercial collaboration. OkaiDx tests are LDTs and are not cleared or approved by the FDA or Health Canada.
YD Bio (Nasdaq: YDES) and affiliate EG BioMed reported a successful presence at BIO Asia-Taiwan 2026, held July 19 at the Washington State Pavilion in Taipei. The companies showcased ophthalmic regenerative medicine, DNA methylation-based oncology diagnostics, and U.S. market-entry services for life science partners.
YD Bio highlighted Exovisse™ preservative-free artificial tears and contact lenses, already authorized for nationwide U.S. sale, and its limbal stem cell exosome therapy program, with an IND for dry eye disease expected in 2026 and first human trials in 2027. EG BioMed presented its telehealth-integrated cancer diagnostics platform and CLIA-certified, CAP-accredited Bothell laboratory, whose licenses now cover 47 U.S. states plus several territories.
According to YD Bio, the companies met over 30 prospective partners and saw particular interest in Exovisse™ collaborations and EG BioMed’s cancer monitoring services. YD Bio also reiterated a previously disclosed non-binding MOU to merge with EG BioMed, anticipated to close in 2026 subject to conditions and approvals.
YD Bio (Nasdaq:YDES) announced that affiliate EG BioMed US has secured out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited Bothell, Washington lab.
These approvals expand its authorized operations to 46 U.S. states plus Washington, D.C. and Guam, supporting blood-based, DNA methylation–based early cancer detection testing and real-world molecular data generation.
YD Bio (Nasdaq: YDES) reported full-year 2025 results: net revenue $596.8K (+17%), gross profit $167.4K, and a net loss $8.31M. Cash and cash equivalents were $6.0M at year-end after an equity raise. The company advanced therapeutics (DMFs filed) and diagnostics (OkaiDx™ validation, EG Telehealth launch).
Management highlighted a completed SPAC business combination, PIPE financing, R&D investment, planned 2026 IND submissions, and ongoing M&A activity.